We also observed that vaccinated tumor-bearing mice treated with DMXAA at the time of vaccination or 3 days before vaccination generated suppressed E7-specific CD8+ T cell immune responses compared to vaccinated mice without DMXAA treatment. Here, CD8A is linked to neoplasm.